Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Very Strong
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Neutral
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Weak
Telephone
61.8.8209.2666
Address
Salisbury South 1538 Main North Road Salisbury, South Australia (SA) 5106
Description
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. It operates through the following segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. The Generic Products segment is involved in the manufacture and distribution of generic and branded pharmaceutical products. The Metrics Contract Services segment provides contract pharmaceutical services. The Specialty Products segment includes the distribution of branded pharmaceutical products. The Mayne Pharma International segment manufactures and sells branded and generic pharmaceutical products and provides contract manufacturing services to third party customers within Australia. The company was founded in 1845 and is headquartered in Salisbury, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 2.75 - 7.46
Trade Value (12mth)
AU$337,499.00
1 week
-7.82%
1 month
-4.39%
YTD
-28.41%
1 year
-5.42%
All time high
37.10
EPS 3 yr Growth
N/A
EBITDA Margin
-65.90%
Operating Cashflow
-$43m
Free Cash Flow Return
-7.00%
ROIC
-51.30%
Interest Coverage
-11.60
Quick Ratio
1.50
Shares on Issue (Fully Dilluted)
81m
HALO Sector
Healthcare
Next Company Report Date
23-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.87
Date | Announcements |
---|---|
25 July 24 |
MYX announces patent lawsuit against Sun Pharmaceutical
×
MYX announces patent lawsuit against Sun Pharmaceutical |
02 July 24 |
Class action settlement
×
Class action settlement |
06 June 24 |
MYX presentation at Jefferies Global Healthcare Conference
×
MYX presentation at Jefferies Global Healthcare Conference |
03 June 24 |
Approval of additional KAPANOL dosages in Switzerland
×
Approval of additional KAPANOL dosages in Switzerland |
28 May 24 |
MYX to present at Jefferies Global Healthcare Conference
×
MYX to present at Jefferies Global Healthcare Conference |
24 May 24 |
Mayne Pharma Market Update
×
Mayne Pharma Market Update |
24 May 24 |
Update - Notification of buy-back - MYX
×
Update - Notification of buy-back - MYX |
24 May 24 |
Notification of buy-back - MYX
×
Notification of buy-back - MYX |
17 May 24 |
Notification of cessation of securities - MYX
×
Notification of cessation of securities - MYX |
13 May 24 |
MYX presentation at Citizens JMP Life Sciences Conference
×
MYX presentation at Citizens JMP Life Sciences Conference |
10 May 24 |
MYX announces two additional patents for Nextstellis granted
×
MYX announces two additional patents for Nextstellis granted |
29 April 24 |
MYX to present at Citizens JMP Life Sciences Conference
×
MYX to present at Citizens JMP Life Sciences Conference |
05 April 24 |
Notification of cessation of securities - MYX
×
Notification of cessation of securities - MYX |
26 March 24 |
Notification regarding unquoted securities - MYX
×
Notification regarding unquoted securities - MYX |
26 March 24 |
Notification of cessation of securities - MYX
×
Notification of cessation of securities - MYX |
18 March 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
12 March 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
11 March 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
05 March 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
28 February 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
27 February 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
26 February 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
26 February 24 |
2024 Half Year Media Release
×
2024 Half Year Media Release |
26 February 24 |
2024 Half Year Investor Presentation
×
2024 Half Year Investor Presentation |
12 February 24 |
Notification of date for release of 1H24 results
×
Notification of date for release of 1H24 results |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.